Furthermore, Tregs expressing CXCR3 co-localize with DCs producing CXCL9 in tumors, which affects the presentation of tumor-derived antigens and dampens the activity of anti-tumor CD8+T cells (Figure 2). The gene discussed is CXCL9; the disease is neoplasm.